

International Agency for Research on Cancer



**Governing Council
Sixtieth Session**

**GC/60/Min.1
18/06/2018**

*Lyon, 16–18 May 2018
Auditorium*

MINUTES OF THE FIRST MEETING

IARC, Lyon

Wednesday 16 May 2018, at 09:15

Chairperson: Professor Mads Melbye (Denmark)

Secretary: Dr Christopher P. Wild, Director, IARC

CONTENTS

	Page
1. Opening of the session	4
2. Election of Rapporteur	4
3. Adoption of the agenda	4
4. Admission of a new Participating State – Iran (Islamic Republic of)	5

Participating State Representatives

Professor Mads MELBYE, <i>Chairperson</i>	Denmark
Dr Stephen M. ROBBINS, <i>Vice-Chairperson</i>	Canada
Ms Lucero HERNANDEZ	
Dr Diane STEBER-BÜCHLI, <i>Rapporteur</i>	Switzerland
Professor Brendan MURPHY	Australia
Ms Elisabeth TISCHELMAYER	Austria
Mr Lieven DE RAEDT	Belgium
Dr Ana Cristina PINHO MENDES PEREIRA	Brazil
Dr Livia DE OLIVEIRA PASQUALIN	
Professor Juhani ESKOLA	Finland
Dr Janne PITKÄNIEMI	
Dr Tuula HELANDER	
Professor Norbert IFRAH	France
Dr Jocelyne BÉRILLE	
Mr Thomas DUBOIS	
Ms Barbara LÜBBEN	Germany
Mr Thomas IFLAND	
Dr Prabha ARORA	India
Dr Fenton HOWELL	Ireland
Dr Mauro BIFFONI	Italy
Dr Pietro COMBA	
Mr Hiroyuki HORI	Japan
Dr Seiichiro YAMAMOTO	
Dr Latifa BELAKHEL	Morocco
Mr Jeroen HULLEMAN	Netherlands
Professor Pål Richard ROMUNDSTAD	Norway
Dr Al-Hareth M. AL-KHATER	Qatar
Dr Haerae KIM	Republic of Korea
Dr Young Joo WON	
Dr Dmitry KOSTENNIKOV	Russian Federation
Dr Igor KOROBKO (<i>unable to attend</i>)	
Dr Eduard SALAKHOV (<i>unable to attend</i>)	
Dr Zoya SEREDA (<i>unable to attend</i>)	
Dr Alexey NOVOZHILOV	
Dr Sergey IVANOV	

Dr Rafael DE ANDRÉS MEDINA	Spain
Dr Karin SCHMEKEL	Sweden
Dr Sandra KLEINAU	
<i>No Representative</i>	Turkey
Dr Mark PALMER	United Kingdom of Great Britain and Northern Ireland
Dr Mariana DELFINO-MACHIN	
Dr Douglas LOWY	United States of America
Dr Ann CHAO	
Dr Gabrielle LAMOURELLE (<i>unable to attend</i>)	
Dr Rachel OWEN	
Dr Lisa STEVENS	
Dr Sarah LLOYD STEVENSON	

World Health Organization

Dr Svetlana AKSELROD, Assistant Director-General, Noncommunicable Diseases and Mental Health

Ms Sigrid KRANAWETTER, Principal Legal Officer, Office of the WHO Legal Counsel

Mr Derek WALTON, WHO Legal Counsel

Observers

Professor Reza Malekzadeh, Iran (Islamic Republic of)

Dr JIE He, President, National Cancer Center of China, China

Dr MIN Dai, Director, Department of International Communications, National Cancer Center of China

Dr Julie TORODE, Deputy CEO, Advocacy and Networks Director, Union for International Cancer Control (UICC)

Professor Giske URSIN, Chairperson, Scientific Council

External Audit

Mr Lito Q. MARTIN, Commission on Audit, Philippines (*unable to attend*)

Secretariat

Dr C.P. WILD, *Secretary*
Dr T. LANDESZ

Dr M. ALMONTE
Dr P. BASU
Ms A. BERGER
Dr F. BRAY
Dr P. BRENNAN
Dr G. CLIFFORD
Dr I. CREE

Ms D. D'AMICO
Dr P. FERRARI
Ms E. FRANÇON
Dr N. GAUDIN
Dr M. GUNTER
Dr Z. HERCEG
Dr R. HERRERO
Dr B. LAUBY-SECRETAN
Dr F. LOZANO
Dr J. MCKAY

Dr R. NJIE
Ms A. SANTHIPRECHACHIT
Dr A. SCALBERT
Dr J. SCHÜZ
Dr I. SOERJOMATARAM
Dr K. STRAIF
Dr M. TOMMASINO
Dr J. ZAVADIL

1. OPENING OF THE SESSION: Item 1 of the Provisional Agenda

The CHAIRPERSON welcomed participants, including new members of the Governing Council, Dr Julie Torode, of the Union for International Cancer Control (UICC) and Dr Svetlana Akselrod, Assistant Director-General, Noncommunicable Diseases and Mental Health, WHO. The meeting would be joined on the following day by two observers from China, Dr Jie He and Dr Min Dai and by Professor Giske Ursin, Chairperson of the Scientific Council.

The SECRETARY expressed pleasure at the growing number of members of the Agency. Welcoming participants, he invited them to view the pictures and a model showing the design of the "Nouveau Centre" which were available in the Princess Takamatsu Hall. Each year, the Governing Council meeting provided an opportunity for the Agency to show its achievements and to describe the support it provided to many collaborators. All of the Agency's remarkable work was carried out as a result of the confidence invested in it by its Participating States. The role of Director required both leadership and service and the present year was particularly special, with the election of a new Director who would take the Agency forward.

2. ELECTION OF RAPPORTEUR: Item 2 of the Provisional Agenda

On the proposal of Dr PALMER (United Kingdom of Great Britain and Northern Ireland), Dr Steber-Büchli (Switzerland) was elected Rapporteur, the proposal being seconded by Professor ESKOLA (Finland).

3. ADOPTION OF THE AGENDA: Item 3 of the Provisional Agenda (Document GC/60/1 (Prov.) Rev.1)

The CHAIRPERSON drew attention to the revised agenda and requested comments thereon.

Dr STEVENS (United States of America) said that the provisional agenda had been well-thought out although she was concerned that insufficient time had been allocated to agenda item 14, which dealt with coordination and communication mechanisms between IARC and WHO. She further requested that consideration should be given to holding future meetings of the Governing Council at a time that did not overlap with the meeting of the WHO Programme, Budget and Administration Committee of the Executive Board (PBAC), which was held in Geneva, in order to allow members of delegations to be present at both meetings.

Dr ROBBINS (Canada, Vice-Chairperson) suggested that additional time could be allocated for discussion of agenda item 14 and that the timing of the next session of the Governing Council could be discussed under agenda item 30.

It was so agreed.

The agenda, as amended, was **adopted**.

**4. ADMISSION OF A NEW PARTICIPATING STATE – IRAN (Islamic Republic of):
Item 4 of the Agenda (Document GC/60/20)**

The CHAIRPERSON said that the Director-General of WHO had communicated the application of the Islamic Republic of Iran to Participating States in September 2017. The documents in relation to the application had been reviewed by the Governing Council Subcommittee on the Admission of New Participating States which had determined that the Islamic Republic of Iran, which had the funding, interest and capacity in cancer research and a national cancer prevention and control plan, met the requirements to demonstrate that it would effectively contribute to the research priorities of IARC as described in its Medium Term Strategy. The Subcommittee therefore recommended that the Governing Council should admit the Islamic Republic of Iran as a Participating State.

The RAPPORTEUR read out the following draft resolution, entitled “Admission of a Participating State – Iran (Islamic Republic of)”, (GC/60/R1):

The Governing Council,

Having examined the request from the Government of Iran (Islamic Republic of) for admission as a Participating State in the International Agency for Research on Cancer (Document GC/60/20),

1. DECIDES pursuant to Article XII of the Statute of the Agency, that Iran (Islamic Republic of) be admitted as a Participating State in the Agency; and
2. EXPRESSES great satisfaction at the admission of this new Participating State.

Professor MALEKZADEH (Islamic Republic of Iran) thanked the Agency for accepting the membership of the Islamic Republic of Iran and recalled the 50 years of collaboration between his country and IARC. Cancer was the second major cause of mortality in the Islamic Republic of Iran after cardiovascular disease. The Islamic Republic of Iran had established the infrastructure for a cancer prevention programme. The country's national cancer control programme was focused on research and recently, with the support of IARC, it had established a national population-based cancer registry. The Golestan Cohort Study on oesophageal cancer, a collaboration between his country and IARC, was the largest cohort study in the WHO Eastern Mediterranean Region (EMRO) and it had produced a contribution of some 200 000 samples for the IARC databank. He looked forward to becoming an active member of IARC and to further collaboration on research on cancer in the EMRO Region.

The resolution was **adopted**.

The meeting rose at 09:40 and resumed in closed session.

During the closed session, agenda items 5 and 6, concerning interviews of candidates for the position of Director, were considered.

The closed part of the meeting rose at 17:45